Benmelstobart

DRUG15 trials

Sponsors

Fudan University, LaNova Medicines Zhejiang Co., Ltd., Shanghai Pulmonary Hospital, Shanghai, China, Xijing Hospital, The First Affiliated Hospital with Nanjing Medical University

Conditions

AnlotinibBenmelstobartBreast CancerBreast NeoplasmBreast TumorsEarly-stage Breast CancerExtensive-stage Small Cell Lung CancerFirst-line Targeted Therapy Failure

Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

RecruitingNCT05582499

Fudan UniversityBreast Cancer, Breast Neoplasm, Breast Tumors +7

Start: 2022-11-01End: 2029-09-01Target: 716Updated: 2026-05-28

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

RecruitingNCT05934331

LaNova Medicines Zhejiang Co., Ltd.Malignant Neoplasms of Digestive Organs

Start: 2023-07-27End: 2031-08-06Target: 632Updated: 2026-10-19

Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

RecruitingNCT06528847

Shanghai Pulmonary Hospital, Shanghai, ChinaNon-Small Cell Lung Cancer

Start: 2024-06-05End: 2030-06-30Target: 62Updated: 2024-07-31

Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC

Not yet recruitingNCT06699498

The First Affiliated Hospital with Nanjing Medical UniversityAnlotinib, Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy +1

Start: 2024-12-03End: 2027-12-01Target: 45Updated: 2024-11-21

Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)

RecruitingNCT06733051

Sun Yat-sen UniversityNatural Killer T-cell Lymphoma

Start: 2024-01-27End: 2028-12-31Target: 47Updated: 2025-02-10

Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy

Not yet recruitingNCT07537777

Nanfang Hospital, Southern Medical UniversityAnlotinib, Benmelstobart, First-line Targeted Therapy Failure +3

Start: 2026-04-20End: 2028-08-31Target: 29Updated: 2026-04-17

Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer

Not yet recruitingNCT07538258

Yayi HeLimited-stage Small Cell Lung Cancer (LS-SCLC)

Start: 2026-04-20End: 2029-03-31Target: 27Updated: 2026-04-20

A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer

Not yet recruitingNCT07538271

Yayi HeSCLC, Extensive Stage

Start: 2026-04-20End: 2029-03-31Target: 33Updated: 2026-04-20

Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC

Not yet recruitingNCT07643350

The Third Xiangya Hospital of Central South UniversityNSCLC

Start: 2026-05-15End: 2031-05-15Target: 152Updated: 2026-06-11

Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma

Not yet recruitingNCT07904819

Sun Yat-sen UniversityNasopharyngeal Cancinoma (NPC)

Start: 2026-12-01End: 2033-12-31Target: 214Updated: 2026-10-29

Phase 3

Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations

Not yet recruitingNCT06955325

The First Affiliated Hospital of Guangzhou Medical UniversityNon-Small Cell Lung Cancer

Start: 2025-05-31End: 2035-12-31Target: 270Updated: 2025-05-06

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Not yet recruitingNCT07385079

Sun Yat-sen UniversityNasopharyngeal Cancer, Nasopharyngeal Cancinoma (NPC)

Start: 2026-03-01End: 2030-01-01Target: 412Updated: 2026-02-03

Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma

Active, not recruitingNCT07881900

Sun Yat-sen UniversityNon-Clear Cell Renal Cell Carcinoma

Start: 2025-06-01End: 2029-06-30Target: 126Updated: 2026-10-20

Phase 4

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Not yet recruitingNCT06931145

Peking Union Medical College HospitalExtensive-stage Small Cell Lung Cancer

Start: 2025-04-15End: 2027-12-31Target: 50Updated: 2025-04-23

Unknown Phase

The Efficacy and Safety of Benmelstobart for GC/EGC

Not yet recruitingNCT06603974

Xijing HospitalGastric Cancer

Start: 2024-10-16End: 2026-12-26Target: 48Updated: 2024-09-19

Related Papers

Multimodal assessment of exceptional responders refines subtyping-directed precision treatment in HR+/HER2– breast cancer

Journal of Clinical Investigation2026-10-14

Efficacy and safety of induction benmelstobart plus anlotinib and chemotherapy followed by concurrent chemoradiotherapy and benmelstobart consolidation versus concurrent chemoradiotherapy followed by benmelstobart consolidation in patients with unresectable stage III NSCLC: a randomized, controlled, multicenter phase II trial protocol (BEAM-LUNG)

Frontiers in Immunology2026-09-25

Precision neoadjuvant treatment with AI-assisted subtyping in HR+/HER2-breast cancer: A randomized, phase 2 trial FASCINATE-N.

2026-08-06

Efficacy and safety of tecotabart vedotin plus toripalimab with or without chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma: Phase II study results.

Journal of Clinical Oncology2026-05-27

Single-cell profiling of natural killer T-cell lymphoma reveals stratified immune features and therapeutic strategies

Blood2025-11-03

Abstract GS1-04: HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial

Clinical Cancer Research2025-06-13

Abstract P2-11-06: Neoadjuvant chemotherapy plus camrelizumab vs. chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer: a prospective, randomized, open-label, phase 2 trial

Clinical Cancer Research2025-06-13

Efficacy and safety of LM-302 (anti-claudin 18.2 ADC) in combination with anti-PD-1 therapy for advanced gastric, gastroesophageal junction cancer and esophageal adenocarcinoma: Early-phase study results.

Journal of Clinical Oncology2025-05-283 citations

Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial

Therapeutic Advances in Medical Oncology2024-01-017 citations